[{"address1": "697 Burke Road", "address2": "Suite 201", "city": "Camberwell", "state": "VIC", "zip": "3124", "country": "Australia", "phone": "61 3 9092 0475", "fax": "61 3 8678 1269", "website": "https://www.tryptherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company's lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Jason  Carroll", "title": "MD, CEO & Executive Director", "fiscalYear": 2024, "totalPay": 882202, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James P. Gilligan MSIB, Ph.D.", "age": 72, "title": "President & Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 307478, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William James Garner M.D.", "age": 58, "title": "Founder & MD", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 39469, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hamish  George B.Com., C.A.", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D.", "age": 75, "title": "Chief Medical Officer", "yearBorn": 1949, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David James Franks BEc, C.A., F Fin, J.P.", "age": 54, "title": "Company Secretary", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.02, "open": 0.02, "dayLow": 0.02, "dayHigh": 0.02, "regularMarketPreviousClose": 0.02, "regularMarketOpen": 0.02, "regularMarketDayLow": 0.02, "regularMarketDayHigh": 0.02, "payoutRatio": 0.0, "volume": 72320, "regularMarketVolume": 72320, "averageVolume": 66178, "averageVolume10days": 31858, "averageDailyVolume10Day": 31858, "bid": 0.0111, "ask": 0.028, "marketCap": 30951400, "fiftyTwoWeekLow": 0.0007, "fiftyTwoWeekHigh": 0.0385, "priceToSalesTrailing12Months": 23.320105, "fiftyDayAverage": 0.015923, "twoHundredDayAverage": 0.014536813, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 22707656, "profitMargins": 0.0, "floatShares": 805639214, "sharesOutstanding": 1276419968, "heldPercentInsiders": 0.38823003, "heldPercentInstitutions": 0.008450001, "impliedSharesOutstanding": 1547570048, "bookValue": 0.003, "priceToBook": 6.6666665, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -7371084, "trailingEps": -0.02, "lastSplitFactor": "1:2.5", "lastSplitDate": 1713139200, "enterpriseToRevenue": 17.109, "enterpriseToEbitda": -4.911, "52WeekChange": 3.0, "SandP52WeekChange": 0.07465422, "quoteType": "EQUITY", "currentPrice": 0.02, "recommendationKey": "none", "totalCash": 2870577, "totalCashPerShare": 0.002, "ebitda": -4624144, "totalDebt": 49795, "quickRatio": 3.694, "currentRatio": 3.865, "totalRevenue": 1327241, "debtToEquity": 1.176, "revenuePerShare": 0.003, "grossProfits": -1020004, "operatingCashflow": -7200070, "grossMargins": -0.76851, "ebitdaMargins": 0.0, "operatingMargins": -3.4901502, "financialCurrency": "AUD", "symbol": "TYPTF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.02, "exchange": "PNK", "messageBoardId": "finmb_693911067", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketTime": 1742328000, "marketState": "REGULAR", "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Tryp Therapeutics Inc.", "nameChangeDate": "2025-03-18", "cryptoTradeable": false, "firstTradeDateMilliseconds": 1720186200000, "regularMarketChange": 0.0, "regularMarketDayRange": "0.02 - 0.02", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 66178, "fiftyTwoWeekLowChange": 0.019299999, "fiftyTwoWeekLowChangePercent": 27.571428, "fiftyTwoWeekRange": "7.0E-4 - 0.0385", "fiftyTwoWeekHighChange": -0.0185, "fiftyTwoWeekHighChangePercent": -0.4805195, "fiftyTwoWeekChangePercent": 300.0, "earningsTimestamp": 1740604277, "earningsTimestampStart": 1740604277, "earningsTimestampEnd": 1740604277, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.02, "fiftyDayAverageChange": 0.0040769987, "fiftyDayAverageChangePercent": 0.25604463, "twoHundredDayAverageChange": 0.0054631867, "twoHundredDayAverageChangePercent": 0.37581736, "hasPrePostMarketData": false, "displayName": "Tryptamine Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-19"}]